Abstract:By definition, biosimilar medicinal products are biological medicinal products that are similar to other biological medicinal products that are already on the market—the reference medicinal products. Access to biosimilar medicines is a current reality. However, to achieve this goal, it is extremely important to consistently and scientifically substantiate the regulatory requirements necessary for biosimilar medicines when accessing the market. Based on an analysis of the raw materials and the type of methods used in the manufacturing processes of biological medicines, it is known that this tends to be more complex for the quality of the finished product than the manufacture of molecules obtained through a chemical process. It is then relevant to highlight the main differences between both products: biological medicines manufactured using biotechnology and the current generics containing active pharmaceutical ingredients (APIs) obtained from synthetic processes. Once arriving at the approval process of these medicinal products, it is imperative to analyse the guidance documents and the regulatory framework that create the rules that allow these biosimilar medicinal products to come to the market. The present review aimed at documenting comparatively the specific provisions of European legislation, through the European Medicines Agency (EMA), as well as the legislation of the United States of America, through the Food and Drug Administration (FDA). This was then translated into a critical appraisal of what concerns the specific criteria that determine the favourable evaluation of a biosimilar when an application for marketing authorisation is submitted to different regulatory agencies. The gathered evidence suggests that the key to the success of biosimilar medicines lies in a more rigorous and universal regulation as well as a greater knowledge, acceptance, and awareness of health professionals to enable more patients to be treated with biological strategies at an earlier stage of the disease and with more affordable medicines, ensuring always the safety and efficacy of those medicines.

"The same thing in a different box": similarity and difference in pharmaceutical sex hormone consumption and marketing

What's in a name? Generics and the persistence of the pharmaceutical brand in American medicine

Brazilian generics market change after Farmácia Popular program

Assessment of the differences between generic and biosimilar drugs: A brief literature review

Beyond health: medicines, food supplements, energetics and the commodification of self-performance in Maputo

Fear, misinformation, and pharmaceutical messianism in the promotion of compounded bioidentical hormone therapy

Interrogating the pill: Rising distrust and the reshaping of health risk perceptions in the social media age

Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap

Hormonal stories: a new materialist exploration of hormonal emplotment in four case studies

Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition

The replacement of the replacement in menopause: hormone therapy, controversies, truth and risk

Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets

Sex Reconfigured: DIY Hormone Therapy and Vernacular Endocrinology in Transfeminine Communities in China

A Regulatory Perspective on Biosimilar Medicines

Gender bias in clinical research, pharmaceutical marketing, and the prescription of drugs

Pharmaceuticalization: AIDS Treatment and Global Health Politics

Experimental Study of the Promotional Implications of Proprietary Prescription Drug Names

Effects of Pharmaceutical Substances with Obesogenic Activity on Male Reproductive Health

Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution

Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions

Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception